J&J(US:JNJ) Zheng Quan Shi Bao Wang·2025-10-15 00:39Group 1 - The company plans to spin off its orthopedic business into an independent company named DePuy Synthes within 18 to 24 months, led by industry veteran Namal Nawana [1] - The company expects revenue growth for the full year 2026 to exceed 5%, surpassing analysts' expectations of 4.6% [1] - The company raised its 2025 product revenue forecast to between $93.5 billion and $93.9 billion, approximately $300 million higher than previous estimates [1] Group 2 - The company's third-quarter sales amounted to $23.99 billion, slightly above Wall Street's expectation of $23.75 billion [1] - The adjusted earnings per share for the third quarter were $2.80 [1] - The orthopedic division generated approximately $9.2 billion in sales last year, accounting for about 10% of the company's total revenue [1]